{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:06:39Z","timestamp":1759032399444},"reference-count":41,"publisher":"Wiley","issue":"s383","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":4709,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[1994,10]]},"abstract":"<jats:p>For a number of years, dysthymia was considered to be non\u2010responsive to antidepressant treatment. During the last decade, early studies with tricyclic antidepressants (TCAs) demonstrated the superiority of the TCAs over placebo. The side effect profile of the TCAs and the moderate degree of symptomatology resulted in reduced compliance and thus to the clinical impression of lack of efficacy. The newest generation of antidepressants, the SRRIs and the RIMAs. with their more acceptable side effect profiles, allowed for the adequate evaluation of pharmacotherapy in dysthymia. The initial open studies with SSRIs indicate a clear efficacy of this group of antidepressants. Likewise, a 5HT<jats:sub>2<\/jats:sub> antagonist, ritanserin, has been shown to be superior to placebo. More recently, a large placebo\u2010controlled study of moclobemide. a RIMA, clearly demonstrated the superiority of this drug over placebo. Based on this evidence, it is now appropriate to consider antidepressants as a clearly effective method of treating dysthymia.<\/jats:p>","DOI":"10.1111\/j.1600-0447.1994.tb05882.x","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T13:06:00Z","timestamp":1187874360000},"page":"42-48","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacological therapy of dysthymia"],"prefix":"10.1111","volume":"89","author":[{"given":"Y. D.","family":"Lapierre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"issue":"150","key":"e_1_2_1_2_2","first-page":"1","volume":"4","author":"American Psychiatric Association","year":"1993","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1176\/appi.psychotherapy.1992.46.1.58","article-title":"A review of treatment studies of minor depression 1980\u20131991","volume":"46","author":"Conte HR","year":"1992","journal-title":"Am J Psychother"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199104000-00003"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1980.01780200055006"},{"key":"e_1_2_1_6_2","first-page":"698","article-title":"Imipramine for the treatment of chronic depression","volume":"21","author":"Kocsis JH","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199300730-00011"},{"issue":"3","key":"e_1_2_1_8_2","first-page":"59","article-title":"Treatment of dysthymia. Overview of therapy options","volume":"4","author":"Kocsis JH","year":"1993","journal-title":"Focus Depression"},{"key":"e_1_2_1_9_2","first-page":"229","article-title":"Recognition and management of dysthymic disorder","volume":"40","author":"Finlayson R.","year":"1989","journal-title":"Am Family Phys"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199400910-00007"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800270071008"},{"key":"e_1_2_1_12_2","first-page":"997","article-title":"Imipramine and social vocational adjustment in chronic depression","volume":"8","author":"Kocsis JH","year":"1988","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(89)90008-6"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674379403900106"},{"key":"e_1_2_1_15_2","first-page":"337","article-title":"A comparison of clomipramine and doxepin in neurotic depression","volume":"45","author":"Kornhaber A","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290090035008"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(88)90075-4"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(88)90053-4"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.151.5.639"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.140.5.475"},{"issue":"1","key":"e_1_2_1_21_2","first-page":"33","article-title":"Tolerance to phenelzine and subsequent refractory depression:three cases","volume":"50","author":"Donaldson SR","year":"1989","journal-title":"J Chi Psychiatry"},{"key":"e_1_2_1_22_2","first-page":"346","article-title":"Phenelzine for chronic depression: a study of continuation treatment","volume":"47","author":"Harrison W","year":"1986","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.158.6.856"},{"key":"e_1_2_1_24_2","first-page":"77","article-title":"Review of comparative clinical trials of moclobemide versus tricyclic antidepressants and versus placebo in depressive states","volume":"28","author":"Stabl M","year":"1989","journal-title":"J Neural Transm Suppl"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246250"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb05323.x"},{"key":"e_1_2_1_27_2","unstructured":"VersianiM CostaDA NardiA MagistrisH Ucha UdabeR CapponiR.A double\u2010blind parallel group multicenter study comparing moclobemide imipramine and placebo in the treatment of patients with chronic depression. Research Report \u2014 Roche Basel Switzerland."},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199202001-00568"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(92)90111-Q"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.8.1169"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430080124"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1991.tb05533.x"},{"issue":"13","key":"e_1_2_1_33_2","first-page":"409","article-title":"Ritanserin, imipramine and placebo in the treatment of dysthymic disorder","volume":"6","author":"Bakish D","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000118485"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.160.1.121"},{"key":"e_1_2_1_36_2","unstructured":"RavindranAV BialikRJ LapierreYD.Primary early onset dysthymia. Biochemical correlates of the therapeutic response to fluoxetine: 1 platelet monoamine oxidase and the dexamethasone suppression test.J Affect Disord(in press)."},{"key":"e_1_2_1_37_2","unstructured":"RavindranAV BialikRJ LapierreYD.Primary early onset dysthymia biochemical correlates of the therapeutic response to fluoxetine. II. Urinary metabolites of serotonin norepinephrine and melatonin.J Arfect Disord(in press)."},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199304000-00008"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.140.6.689"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820100053010"},{"key":"e_1_2_1_41_2","doi-asserted-by":"crossref","unstructured":"BechP Mellerg\u00e5rdM.OttosonJO.Secondary depression in panic disorder: an indicator of severity with a weak effect on outcome in alprazolam and imipramine treatment.Acta Psychiatr Scand1991:suppl 365:39\u201345.","DOI":"10.1111\/j.1600-0447.1991.tb03100.x"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.149.4.443"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.1994.tb05882.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.1994.tb05882.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T07:43:48Z","timestamp":1695800628000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.1994.tb05882.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,10]]},"references-count":41,"journal-issue":{"issue":"s383","published-print":{"date-parts":[[1994,10]]}},"alternative-id":["10.1111\/j.1600-0447.1994.tb05882.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.1994.tb05882.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,10]]}}}